ValiRx plc

0.14pAs of Sun 8 Nov 2026, 12:00 UTC

LSE:VALHealthcare

Ctry United Kingdom

PE (Fwd) •••

TSR 10Y CAGR (58.12%)

Div yield —

ROE (77.28%)

Biotechnology

Beta (5Y) (0.41)

PE TTM —

TSR TTM (44.00%)

Mkt cap £1.848M

ROIC (37.75%)

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

0.157p

12.38%

2.92%

Hold 8|11|2|1|3

TTM

FYE 31 Dec GBP

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

5Y

10Y

Peers

0.093

Revenue£M

0.203

0.216

0.231

0.245

0.263

0.283

0.311

0.331

0.355

0.392

0.103

8.31%

7.61%

52

5.37

Revenue growth%

29.20

26.52

28.37

30.43

28.53

28.66

27.99

28.43

31.16

29.21

12.92

28.66

28.60

51

6.83

Gross margin%

0.40

2.26

3.37

6.34

4.52

4.14

5.96

7.07

5.47

8.41

21.55

5.96

4.99

63

20.44

Operating margin%

22.55

23.84

21.38

23.82

23.08

23.90

26.74

25.11

25.84

24.47

22.00

25.11

23.87

8

24.77

Net margin%

2.79

1.74

0.40

1.29

2.45

2.52

0.40

1.89

0.80

1.07

5.58

1.07

1.52

80

25.93

P/E ratio (avg)x

39.51

47.81

58.17

60.35

72.56

77.85

94.36

99.07

108.0

110.5

22.24

99.07

75.20

76

25.74

EV/EBITx

8.105

7.863

8.146

8.118

7.644

6.870

6.552

5.984

5.695

5.434

11.78

5.984

7.257

70

17.48

FCF yield (avg)%

5.06

2.31

5.06

4.91

4.70

6.26

6.30

6.07

5.44

7.42

24.24

6.26

5.25

23

14.60

FCF margin%

0.40

0.40

0.40

0.53

0.41

0.52

0.40

0.40

2.04

2.62

3.12

0.52

0.41

13

0.832

FCF / Net incomex

0.396

0.407

0.421

0.452

0.420

0.433

0.445

0.464

0.419

0.444

0.386

0.444

0.427

37

12.62

ROIC%

7.72

5.38

3.01

4.56

6.77

5.10

3.42

6.29

5.78

5.11

17.89

5.11

5.25

44

27.37

Return on equity%

20.52

21.65

22.32

21.57

24.02

21.19

21.62

23.21

24.81

25.57

23.79

23.21

21.99

15

22.51

Return on assets%

32.89

31.47

33.32

34.08

32.86

32.22

32.97

30.96

33.43

34.75

17.87

32.97

32.93

54

—

EPS£

—

—

—

—

—

—

—

—

—

—

—

9.83%

6.91%

—

9.72

EPS growth%

3.27

1.06

0.40

0.50

3.14

2.98

5.45

2.53

3.83

6.22

29.46

3.83

3.06

33

—

Bookvalue per sh£

—

—

—

—

—

—

—

—

—

—

—

(0.42%)

(1.13%)

—

—

FCF per share£

—

—

—

—

—

—

—

—

—

—

—

(2.12%)

(0.65%)

—

—

Dividend per sh£

—

—

—

—

—

—

—

—

—

—

—

2.43%

1.35%

—

5.42

Div yield (avg)%

29.35

27.79

26.38

28.09

29.70

30.82

32.04

33.13

30.36

27.87

12.00

30.82

29.53

75

7.77

Payout ratio%

28.37

25.83

23.33

24.99

24.25

25.22

27.67

26.89

28.05

29.41

14.92

27.67

26.36

30

1.344

Shares (diluted)B

2.163

2.092

2.136

2.161

2.440

2.817

3.383

3.764

4.160

4.496

1.287

13.00%

9.25%

45

27.27

Buyback yield%

8.07

9.08

6.22

8.82

9.99

8.87

6.02

6.62

8.83

11.20

20.52

8.83

8.83

28

0.827

D/E ratiox

0.587

0.523

0.541

0.585

0.567

0.617

0.577

0.603

0.553

0.487

0.216

0.577

0.572

30

0.205

Enterprise value£M

0.159

0.154

0.159

0.176

0.161

0.161

0.174

0.159

0.172

0.155

0.374

(0.81%)

(0.52%)

29

0.151

LT debt£M

0.284

0.287

0.288

0.318

0.319

0.346

0.319

0.351

0.350

0.376

0.356

3.34%

1.76%

93

Peers (US$2.665M)

Cap (US$)

PE

3.863M

—

BSF Enterprise Plc

2.468M

—

2.387M

—

Onconetix, Inc.

2.745M

—

Capital

TTM

5Y

10Y

Leveragex

2.196

0.908

0.885

EBIT/Intx

22.06

0.100

0.100

Own earn%

(90.92)

66.99

94.85

Sh yield%

32.69

39.19

38.56

Owners

Insiders/Inst%

1.54

21.25

Short interest%

1.42

SBC / revenue%

3.87

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

7

Op margin range%

21–27

$1 testx

0.0

Incr. ROIC%

7

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

£0.392M

7.61%

1.00×

Cost of revenue

£0.266M

7.52%

0.99×

Operating expenses

£0.060M

7.91%

1.03×